Vaccine protection against the SARS-CoV-2 Omicron variant in macaques.
Cell
; 185(9): 1549-1555.e11, 2022 04 28.
Article
in English
| MEDLINE | ID: covidwho-1748149
ABSTRACT
The rapid spread of the SARS-CoV-2 Omicron (B.1.1.529) variant, including in highly vaccinated populations, has raised important questions about the efficacy of current vaccines. In this study, we show that the mRNA-based BNT162b2 vaccine and the adenovirus-vector-based Ad26.COV2.S vaccine provide robust protection against high-dose challenge with the SARS-CoV-2 Omicron variant in cynomolgus macaques. We vaccinated 30 macaques with homologous and heterologous prime-boost regimens with BNT162b2 and Ad26.COV2.S. Following Omicron challenge, vaccinated macaques demonstrated rapid control of virus in bronchoalveolar lavage, and most vaccinated animals also controlled virus in nasal swabs. However, 4 vaccinated animals that had moderate Omicron-neutralizing antibody titers and undetectable Omicron CD8+ T cell responses failed to control virus in the upper respiratory tract. Moreover, virologic control correlated with both antibody and T cell responses. These data suggest that both humoral and cellular immune responses contribute to vaccine protection against a highly mutated SARS-CoV-2 variant.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
SARS-CoV-2
/
COVID-19
/
BNT162 Vaccine
/
Ad26COVS1
/
Macaca
Type of study:
Experimental Studies
Topics:
Vaccines
/
Variants
Limits:
Animals
Language:
English
Journal:
Cell
Year:
2022
Document Type:
Article
Affiliation country:
J.cell.2022.03.024
Similar
MEDLINE
...
LILACS
LIS